# CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors

> **NCT06567366** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** CAR T-cell therapy
- **DRUG:** Glofitamab
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT06567366
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06567366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06567366, "CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06567366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*